Quest PharmaTech Inc., a pharmaceutical company, develops targeted cancer therapies in Canada. Its lead product is MAb AR9.6, a theranostic agent for cancer in preclinical development for pancreatic cancer. The company is headquartered in Edmonton, Canada.
Research context
Quest PharmaTech Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Quest PharmaTech Inc is currently in a long term downtrend where the price is trading 34.3% below its 200 day moving average.
From a valuation standpoint, the stock is 49.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 516.0.
Quest PharmaTech Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 336.0% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 93.8% to $-103K since the same quarter in the previous year.
Based on the above factors, Quest PharmaTech Inc gets an overall score of 3/5.